IMPORTANT SAFETY INFORMATION:
NEXAVAR is contraindicated in patients with known severe hypersensitivity to sorafenib or any other component of NEXAVAR. Continue reading below

Prescribing Nexavar

Dose modifications

The following may require temporary interruption or permanent discontinuation1:

  • Cardiac ischemia or infarction, hemorrhage requiring medical intervention, severe or persistent hypertension despite adequate anti-hypertensive therapy, gastrointestinal perforation, QTc prolongation, or severe drug-induced liver injury

Temporary interruption of NEXAVAR is recommended in patients undergoing major surgical procedures.1

Dosage modifications for patients with uHCC and aRCC

When dose reduction is necessary, the NEXAVAR dose may be reduced to 400 mg once daily. If additional dose reduction is required, NEXAVAR may be reduced to a single 400 mg dose every other day.

Staging and Treatment Strategy Indication 3 Button

Photos courtesy of Elizabeth Manchen, RN, MS, OCN. Reproduced with patients' permission.

Indications

NEXAVAR is indicated for the treatment of patients with unresectable hepatocellular carcinoma (HCC).

NEXAVAR is indicated for the treatment of patients with advanced renal cell carcinoma (RCC).

NEXAVAR is indicated for the treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma (DTC) that is refractory to radioactive iodine treatment.

Important Safety Information

For important risk and use information about NEXAVAR, please see the full Prescribing Information.

INDICATION and IMPORTANT SAFETY INFORMATION for STIVARGA® (regorafenib)

For important risk and use information about STIVARGA, please see the full Prescribing Information including the Boxed Warning.

You are encouraged to report negative side effects or quality complaints of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

REFERENCE:

1. NEXAVAR Prescribing Information. Whippany, NJ: Bayer HealthCare Pharmaceuticals, Inc.